Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Alberto Zaniboni, Maria Banzi et al.|The Oncologist|2018Cited by 143
KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated AnalysisMarc Peeters, Scott D. Patterson, Kelly S. Oliner et al.|Annals of Oncology|2014Cited by 3